Want to join the conversation?
$JNJ said Janssen Pharmaceuticals, an affiliated company, is terminating its licensing agreement with $AMGN for fulranumab and is returning all program rights back to Amgen. Fulranumab is part of an experimental class of non-opioid biological medicines called anti-nerve growth factor compounds.
Any idea why some investors are happy about the disastrous $UA results??
Wow! GM killed it with earnings today! Did not expect this after $F gave the feeling it will eclipse the Chevy maker completely!
Oil rebound starting to show up in energy stocks. $XOM $CVX
I have a feeling "CLOUDy" days are ahead, with $AMZN leading the pack.
$AAL is giving pay hikes to its employees but investors are sulking.